150 £

Lyrica is the brand name for pregabalin, a prescription medicine widely used for certain types of nerve pain and for fibromyalgia, and it’s also used as add-on therapy for partial-onset seizures. What makes pregabalin especially notable is how often it’s prescribed for pain that doesn’t feel “typical” (burning, tingling, electric shocks, hypersensitivity)—the kind of symptoms many people struggle to explain, yet can be very real and disruptive. The FDA-approved uses for Lyrica include neuropathic pain from diabetic peripheral neuropathy, postherpetic neuralgia (shingles nerve pain), spinal cord injury, plus fibromyalgia, and seizure adjunct therapy.

The iMedix Lyrica page is built to be genuinely useful if you’re trying to understand whether pregabalin is “the right category” of medication for your situation. It explains what Lyrica is meant to help with, what people typically notice first, and what’s realistic to expect (and what isn’t). It also highlights a practical point many patients miss: don’t stop it suddenly—the prescribing information recommends tapering gradually (at least one week) to reduce risks like withdrawal symptoms and seizure risk.

Safety is covered clearly and without alarmism. Lyrica can cause dizziness and sleepiness, which can affect driving and focus, and there’s a serious warning about respiratory depression risk—especially if used with other CNS depressants (including opioids) or in people with underlying breathing impairment.

Finally, for anyone wondering why it’s regulated differently than many non-opioid pain meds: pregabalin is a U.S. Schedule V controlled substance, reflecting a recognized (though lower) abuse potential compared with higher schedules. iMedix mentions these context details so readers can stay informed, ask better questions, and use prescriptions responsibly.